Pharmaceuticals, Biotechnology and Life Sciences
Neovacs has received a first payment of a total amount up to €702.000, for its preclinical development program AllergyVacs, within the grant awarded by the National Agency for Research (ANR), conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute.
appointment of Dr. Virginia Pascual as Medical and Scientific advisor.
“We are delighted to welcome Dr Pascual to Neovacs. Her significant contribution to lupus research and practical knowledge of new treatment approaches, and in particular the role of interferon alpha1, will be key to the next stage of Neovacs’ development. This will be of particular importance for the phase 3 clinical trial protocol and for all others pathologies linked to the neutralization of Interferon alpha such as the ongoing Type 1 Diabetes program” said Miguel Sieler, CEO of Neovacs.”
Dr. Virginia Pascual, MD, is the Founding Director of the Gale and Ira Drukier Institute for Children’s Health at Weill Cornell Medicine in New York City. Her research work has been published in many prestigious scientific revues, she has received multiple awards for her discoveries, from the National Institute of Allergy & Infectious Diseases, and in 2017 the “Lupus Insight Prize” for highly promising research into understanding the events leading to lupus flares.
Before joining the Drukier Institute in New York, Dr Pascual served at the Baylor Institute for Immunology Research in Dallas as Director of the Centre for Inflammation and Genomics. She received her medical degree at the Universidad Complutense in Madrid and specialised in pediatric rheumatology at UT Southwestern Medical Center in Dallas, TX.
As of today, the IFNa Kinoid is the only therapeutic vaccine that has brought positive clinical phase IIb results applying the LLDAS score. This has allowed the clinical and scientific community to envisage a clinical improvement in a patient’s condition enabling a significant reduction in corticosteroid treatments.
As a reminder, lupus is a complex disease with multiple symptoms and the LLDAS is a promising clinical score having reached a wide consensus among the medical and scientific community worldwide. LLDAS has very recently been accepted as primary clinical endpoint by the Chinese FDA.
The U.S. Food and Drug Administration (FDA) has cleared Neovacs’s Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.
Neovacs has completed patient enrollment for for its phase IIb clinical study, IFN-K-002, evaluating IFNalpha Kinoid for the treatment of lupus.
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.
Neovacs’s Scientific Advisory Board has recommended extension of the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018.
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…
The U.S. Food and Drug Administration (FDA) has granted “Fast Track” status to French biopharmaceutical company Neovacs’s IFNalpha Kinoid in…
Neovacs, a player in active immunotherapy for the treatment of autoimmune diseases, has enroled the first U.S. patient in its international Phase IIb clinical study of IFNalpha Kinoid in lupus.
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board